Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 8Terminated 3Active not recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 8Sarcoma 4CNS 4Tumor-Agnostic 3Lymphoid 3Gastrointestinal 3Thoracic 2Other hematologic neoplasm 2Myeloid 2Head & Neck 2Gynecologic 2Breast 2Other solid neoplasm 1Dermatologic 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Carcinoma, Squamous Cell 1

Interventions

Gemcitabine 13pembrolizumab 12Capecitabine 9Irinotecan 8Erlotinib Hydrochloride 8Carboplatin 8Blood Specimen Collection 8Nivolumab 7Docetaxel 7Cisplatin 7Cetuximab 7Paclitaxel 6Everolimus 6130-nm albumin-bound paclitaxel 6vadimezan 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cyclophosphamide 5trametinib 4Leucovorin 4Lapatinib 4Ipilimumab 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3atezolizumab 3abemaciclib 3Trastuzumab 3Radiotherapy 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × temsirolimus × Tumor-Agnostic × Clear all
NCT01529593 2025-03-24

Temsirolimus in Combination With Metformin in Patients With Advanced Cancers

M.D. Anderson Cancer Center

Phase 1 Terminated
34 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01378377 2018-07-30

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

EMD Serono

Phase 1 Terminated
33 enrolled 21 charts
Tumor-Agnostic

Neoplasms

NCT01009203 2015-08-10

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

New Mexico Cancer Research Alliance

Phase 2 Terminated
13 enrolled 8 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡